Search results
Showing 1 to 15 of 36 results for abiraterone
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Evidence-based recommendations on abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults.
NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
Show all sections
Sections for TA1032
In development Reference number: GID-TA11558 Expected publication date: TBC
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)
Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.
We are listening to your views on this Technology appraisal guidance. Comments close 19 June 2026.
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Evidence-based recommendations on cabazitaxel (Jevtana) for people with prostate cancer that has come back after it was treated with docetaxel.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.